CINCINNATI, Aug. 9 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research
"Medical know-how is critical to the success of any clinical program, especially the design, review and implementation of clinical trial protocols," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer. "Dr. Gallagher's broad and diverse medical knowledge as well as his extensive clinical trials experience will further strengthen our ability to contribute high-level, strategic therapeutic advice to meet our customer's clinical development goals."
Dr. Gallagher served most recently as the Global Gastrointestinal Therapeutic Area Group Leader for ICON Clinical Research where he also served in roles of increasing responsibility throughout his tenure, including Medical Director and Associate Medical Director for the Medical Affairs group. Prior to joining ICON, he served as Associate Medical Director of Medical and Scientific Affairs and Clinical Operations Manager for Medex Clinical Trials Services and PharmaNet, SMO Physician Manager for Focused Managed Research and Medical Consultant to Medi Media, a medical communications company. Dr. Gallagher's background includes working in diverse therapeutic areas across all phases of drug development, with particular expertise in gastrointestinal medicine, CNS, rheumatology, respiratory disease, pain management, infectious disease and genitourinary disorders.
Dr. Gallagher earned his medical degree from the Universidad Federico Henriquez y Carvajal School of Medicine and a Bachelor of Science from the State University of New York at Albany. He also holds a Doctor of Chiropractic degree from the Palmer College of Chiropractic and is a veteran of the United States Navy.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.
SOURCE Kendle International Inc.
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All